Alectinib: A Review in Advanced, ALK-Positive NSCLC

Drugs
Julia Paik, Sohita Dhillon

Abstract

Alectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with advanced ALK-positive NSCLC previously treated with crizotinib. In the USA, alectinib is indicated for the treatment of adults with ALK-positive metastatic NSCLC. The recommended dosage for alectinib in the EU and USA is 600 mg twice daily. Well-designed phase III studies in patients with ALK-positive NSCLC showed that during up to ≈ 19 months' follow-up, progression-free survival (PFS) was significantly improved with alectinib relative to crizotinib as first-line therapy (ALEX study), and relative to chemotherapy in patients previously treated with crizotinib and platinum-doublet chemotherapy (ALUR study). Central nervous system (CNS)-related outcomes were significantly improved with alectinib in both these settings. Two phase II registrational studies (NP28673 and NP28761) in patients previously treated with crizotinib also demonstrated the efficacy of alectinib, as assessed by objective response rates (ORRs), during up to 21 months'...Continue Reading

References

Mar 12, 2009·Expert Review of Anticancer Therapy·Thomas R WebbStephan W Morris
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T ShawA John Iafrate
Jun 4, 2013·The New England Journal of Medicine·Alice T ShawPasi A Jänne
Sep 11, 2014·Cancer Chemotherapy and Pharmacology·Tatsushi KodamaHiroshi Sakamoto
Sep 18, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryohei KatayamaAlice T Shaw
Oct 29, 2014·Molecular Cancer Therapeutics·Tatsushi KodamaHiroshi Sakamoto
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
May 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryohei KatayamaAlice T Shaw
Nov 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sai-Hong Ignatius OuDong-Wan Kim
Dec 3, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wenyin Shi, Adam P Dicker
Jan 12, 2016·Therapeutic Advances in Medical Oncology·Ivana Sullivan, David Planchard
Aug 31, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Dagogo-Jack, A T Shaw
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S NovelloUNKNOWN ESMO Guidelines Committee
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators
Jun 29, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Toshito NakagawaMasaki Ishigai
Apr 19, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S NovelloJ Wolf

❮ Previous
Next ❯

Citations

Aug 22, 2020·World Journal of Clinical Oncology·Victoire de SalinsEmmanuelle Kempf
Apr 15, 2020·Cancers·Abdulaziz B Hamid, Ruben C Petreaca
Oct 9, 2021·Journal of Medicinal Chemistry·Cecilia C Ayala-AguileraAsier Unciti-Broceta
Jan 19, 2022·Pancreas·Zhengzheng WangJinxue Zhou

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.